NEW YORK, Sept. 21, 2026 /PRNewswire/ — Generate Capital (“Generate”), a leading investor, owner and operator of critical infrastructure today announced the 100% sale of Generate Upcycle “Upcycle“, its global anaerobic digestion platform, through two separate transactions in North America and the UK.

Pinta Energy, a UK-based renewable energy platform and part of the ABIO Group of companies, a leading pan-European biogas platform backed by Asterion Industrial Partners, has acquired Upcycle’s seven UK facilities.

Vanguard Renewables, a leading U.S. environmental services platform and producer of biomethane from organic waste, has signed an agreement to acquire Upcycle’s five North American facilities in Ontario, Canada and upstate New York. The transaction is expected to close on October 1, 2026.

The transactions position the businesses with strategic operators to support their next phase of growth.

“We have spent the past decade building Upcycle into a scaled organic waste platform with strong businesses across three countries,” said David Crane, CEO of Generate Capital. “Pinta Energy and Vanguard Renewables bring the experience and capabilities to support these businesses as they continue to grow. For Generate, the transactions allow us to recycle capital toward our strategy of delivering reliable power to large energy users in an increasingly constrained grid.”

Upcycle is a renewable natural gas and electricity production platform that provides integrated organic waste solutions to public and private-sector partners across Canada, the United States and the United Kingdom. In 2025, Upcycle processed more than 871,000 tons of food and agricultural waste, and generated more than 365,000 MWh of renewable energy, including 1.1 billion cubic feet of renewable nature gas. As a result, the company avoided 609,739 MTCO2e tons of harmful emissions from escaping into the atmosphere, the equivalent of taking approximately 132,552 gasoline-powered passenger vehicles off the road for a year.

Generate has invested in anaerobic digestion since 2016, building Upcycle into one of the largest pure-play organic waste platforms, with 12 facilities across three countries. Through sustained investment in the platform, its management team and operations, Generate helped build businesses with strong operating track records that are well positioned for continued growth in their respective markets.

About Generate Capital

Generate Capital is an investor and operator providing reliable and affordable energy solutions to customers for over a decade. Founded in 2014, Generate focuses on accelerating the energy transition by helping large energy users access power and connection faster in a grid constrained world. The firm supports data centers and other power-intensive facilities with multi-technology scalable energy infrastructure solutions, combining deep investment expertise with hands-on operating capabilities. Since inception, Generate has raised more than $16 bn in capital and built a proven track record across critical infrastructure assets. 

For more information, visit www.generatecapital.com.

About Vanguard Renewables

Vanguard Renewables is a leading U.S. environmental services company and producer of biomethane from organic waste. Headquartered in Weston, Massachusetts, the company builds, owns, and operates on-farm anaerobic digesters that convert food, beverage, and agricultural waste into pipeline-ready renewable natural gas. Vanguard Renewables is rapidly scaling its footprint, operating sites across the Northeast, Midwest, and Southeast while developing additional facilities nationwide. By diverting organic waste streams from landfills, the company is reducing greenhouse gas emissions at scale while supporting critical domestic energy infrastructure and regenerative agriculture for America’s farms. Vanguard Renewables is a portfolio company of Global Infrastructure Partners (GIP), part of BlackRock.

Learn more at www.vanguardrenewables.com

SOURCE Generate Capital

NEW YORK, Sept. 21, 2026 — Lazard, Inc. (NYSE: LAZ) announced today that Matt Spence joined the firm as Head of Defense Technology and Emerging Technology in the Technology Group, based in San Francisco.

Matt will advise defense, security, and other cutting-edge technology companies on M&A transactions as well as financings. He joins Lazard with a blend of government service, venture investing, and banking leadership.

“Few bankers can speak to defense and dual-use technology from multiple angles the way Matt can,” said Mark Dolins, Head of the Technology Group at Lazard.  “His arrival at the firm strengthens the coverage we can offer across defense and emerging technology and gives our clients a partner who deeply understands the industry.”

Most recently, Matt was Managing Director and Global Head of Venture Capital Banking at Barclays, where he built and led the firm’s defense-tech and dual-use technology investment banking franchise. He previously held senior roles at Guggenheim Partners and as a Partner at Andreessen Horowitz, and spent seven years in senior national security positions within the U.S. government, including as Deputy Assistant Secretary of Defense for Middle East Policy and on the White House National Security Council.

“Defense and dual-use technology are being reshaped by capital, policy, geopolitical forces, and innovation all at once, and Lazard’s platform is uniquely built to advise companies through that shift,” said Matt Spence. “I’m thrilled to join a firm with this level of expertise and relationships, and I look forward to helping clients across the full lifecycle of defense and emerging technology transactions.”

Matt holds a Doctorate in International Relations from Oxford University, a J.D. from Yale Law School, and a B.A. and M.A. in International Policy Studies from Stanford University. Matt is a cofounder of The Truman National Security Project and a life member of the Council on Foreign Relations.

Founded in 1848, Lazard is the preeminent financial advisory and asset management firm, with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. Lazard is listed on the New York Stock Exchange as Lazard, Inc. under the ticker LAZ. For more information, please visit Lazard.com and follow Lazard on LinkedIn.

Media Contacts

Shannon Houston, +1 212-632-6880
[email protected]

Jessica Francisco, +1 212-632-6571
[email protected]

Investor Contact        

William Murdock, +1 212-632-1564
[email protected] 

SOURCE Lazard

Breakthrough High Efficiency Fiber Technology Enables Uranium Adsorption from Seawater Rather Than Mined from Rock

LOS ANGELES, Sept. 21, 2026 — Fluxnium, Inc. (Fluxnium), a pioneer of domestic uranium supply adsorbed from seawater, today announced a $7 million seed round led by Congruent Ventures, with participation from Constellation Technology Ventures, the venture investing organization within Constellation (NASDAQ: CEG), the nation’s largest producer of reliable and clean energy, and Active Impact Investments, Canada’s largest climate technology seed fund. The funding catalyzes the commercialization of a new secure source of uranium, the critical mineral that underpins both the civilian nuclear fuel cycle and the defense supply chain. Proceeds will go towards further development, pilot testing and scale-up of Fluxnium’s technology platform.

The largest uranium supply on Earth is not underground; it is dissolved in the ocean. Seawater holds centuries’ worth of supply for the global uranium market — roughly a thousand times more than all currently identified terrestrial deposits combined. The challenge is that dissolved uranium exists at very low concentrations. Fluxnium addresses this challenge through its proprietary high-surface-area fiber, recently developed with a leading U.S. national laboratory, that passively adsorbs uranium as seawater moves past it.

“The United States imports more than 90% of its uranium supply at a time when nuclear power is increasingly seen as a solution to growing demand for electricity driven by economic growth,” said Jeff Green, CEO and Founder of Fluxnium. “Fluxnium is developing a new domestic and sustainable supply of uranium, passively adsorbed from seawater on proven offshore infrastructure — at a cost projected to compete with conventional mining, with no tailings or ground water concerns.”

Fluxnium’s fiber deploys on longline systems in open water — the same passive marine infrastructure proven by seaweed and mussel farms — then is retrieved, processed, and redeployed. With accelerating demand for nuclear power, plant operators are very interested in cost-competitive and sustainable fuel supply beyond uranium mining.  Traditional uranium production projects can require significant time, capital investment and regulatory review before reaching commercial operation. Adsorption from seawater addresses those concerns, and the approach expands production by deploying additional fiber rather than developing a new mine.

“With the current uranium market dynamics, there is a new path to making the ocean one of the lowest-cost sources in the world,” said Kevin Kopczynski, Partner at Congruent Ventures. “Congruent is excited to support Fluxnium as it unlocks the ocean’s potential as a major contributor to a diverse and robust domestic nuclear fuel supply chain.”

“Innovations that could expand domestic sources of uranium are important areas of research for the nuclear energy industry,” said Jason Murphy, Vice President of Nuclear Fuels, Constellation. “Fluxnium’s technology has the potential to broaden future fuel supply options and support growing demand for clean, reliable nuclear energy.”

“With global nuclear power generation projected to increase 2.5X in the next 15 years, Fluxnium is the future of uranium supply with clean, lower cost ocean adsorption displacing the environmental damage from mining and tailings,” said Tom Boddez, General Partner at Active Impact Investment. “We have strong conviction that Jeff and co-founder Jim McDermott, with their prior successes taking hardtech ideas to commercial reality, are the ideal team to seize this opportunity.”

About Fluxnium

Fluxnium is building a new domestic supply of uranium — adsorbed from seawater rather than mined from rock. Using high-efficiency adsorbent fiber developed with a leading U.S. national laboratory, Fluxnium passively adsorbs uranium already dissolved in seawater at a cost projected to match conventional mining. With the ocean containing centuries of uranium supply, capacity grows by deploying more fiber — becoming a production decision rather than a long-term capital investment for mine construction. And because there is no mine, there are no tailings or ground water concerns, which eliminates the slowest and most contested steps of conventional permitting. Deployed on the same infrastructure proven in offshore aquaculture, Fluxnium’s mission is to make the ocean the lowest-cost source of uranium in the world. For more information, visit https://fluxnium.com

About Congruent Ventures

Congruent Ventures is an early-stage, climate-focused venture capital firm founded in 2017. The firm backs North American founders from formation through Series A across five sectors: Energy Abundance, Agriculture + Food, Industry + Efficiency, Mobility + Built Environment, and Resilience + Restoration. Congruent manages over $1B in AUM across three early-stage funds and one later-stage fund, and has backed 60+ companies to date. Learn more at congruentvc.com.

About Constellation Technology Ventures

Constellation Technology Ventures (CTV) is the venture investing organization within Constellation, the United States’ largest producer of clean, carbon-free energy and a leading supplier of energy products and services to businesses, homes, community aggregations and public sector customers. CTV invests in companies exploring innovative energy technologies and business models, building a portfolio that represents a broad range of development stages and technology types. CTV’s participation represents a venture investment in the continued development of Fluxnium’s technology and does not constitute a fuel-purchase commitment at this time.

About Active Impact Investments

Active Impact Investments is Canada’s largest climate tech seed fund, managing three funds and $180M in assets from Vancouver, British Columbia. We are helping build the future of production and consumption by investing in early-stage companies that solve the most urgent environmental challenges while achieving venture scale. We look for capital-efficient, market-ready businesses that deliver cheaper, better solutions with immediate customer ROI. Beyond capital, we dedicate our time to the areas founders need most: sales, talent and fundraising, supported by a global network of operators and investors. Active Impact is a Certified B Corp.

Media Contact

Jeff Green

CEO & Founder

[email protected]

SOURCE Fluxnium Inc.

SINGAPORE, Sept. 20, 2026 — 01F Group through its growth-stage fintech private equity arm, 01Fintech, today announced its investment in DANA, Indonesia’s leading digital financial platform. The investment reflects 01F Group’s commitment to supporting resilient, locally rooted technology infrastructure that advances financial inclusion and supports Indonesia’s real economy. It also strengthens the Group’s presence in Asia’s fintech sector and reflects its conviction that Indonesia remains one of the region’s most dynamic digital-payments markets, underpinned by high digital adoption, a large consumer base and growing demand for technology-enabled financial services.

As Southeast Asia’s largest digital economy evolves, digital payments have become an essential part of everyday commerce for consumers and small businesses. Indonesia’s digital economy continues to expand rapidly, with digital payments projected to approach USD1 trillion by 2030.

DANA is a leading Indonesian digital e-wallet and digital financial services platform that serves consumers, merchants and financial institutions through a single, integrated ecosystem. Its scale and reach underscore the strength of its platform, including metropolitan and non-metropolitan regions and supports millions of users and micro, small, and medium enterprises (MSMEs), especially across Tier 2 to Tier 4 regions.

01F Group invests in category-defining platforms distinguished by sustainable unit economics, strong local execution, and meaningful utility for the communities they serve. Through this partnership, 01F Group leverages 01Fintech’s sector expertise and regional network to support DANA’s continued growth and the expansion of its financial-services offering.

Kenny Man, Founder and Managing Partner of 01F Group, stated:

“Our investment in DANA is grounded in three core convictions: the platform’s exceptional operational discipline, its essential role in empowering local MSMEs, and the team’s unwavering resilience. We are not just capital providers; we look forward to being a long-term partner to DANA as it continues to strengthen Indonesia’s digital financial infrastructure and broaden access to trusted financial services.”

Vince Iswara, Chief Executive Officer and Co-founder of DANA, said:

“We are pleased to welcome 01Fintech to DANA’s journey. Beyond capital, 01Fintech brings specialized fintech expertise, strategic regional connectivity, and a shared commitment to sustainable growth. Together, we remain focused on strengthening our core platform, supporting everyday merchants, and providing trusted financial tools to communities across Indonesia.”

Unlocking Ecosystem Value & Strategic Synergy

The investment strengthens 01F Group’s footprint in the regional fintech value chain. 01Fintech and DANA will explore opportunities to create value across the broader ecosystem, including:

• Expand Credit & Capital Access: Connect MSMEs on the DANA platform with scalable lending and working capital solutions.
• Broaden access to financial services: Supporting access to products such as micro-insurance, digital savings and wealth-building tools for underserved users.
• Support regional connectivity: Leveraging 01F Group’s network to explore more efficient cross-border payment solutions for Indonesian merchants and consumers

01F Group and DANA share a commitment to using technology to support the real economy and create durable value for Indonesian businesses and consumers.

About 01F Group

01F Group is a global investment platform that backs visionary founders and CEOs building next generation technology leaders. The Group combines specialised capital with deep operational partnership to help companies bridge innovation and execution, making digital ecosystems more accessible and scalable. Through a family of focused funds, 01F Group supports companies at different stages of their growth journey: 01Fintech, a growth-stage, Asia-focused private equity strategy that empowers fintech entrepreneurs to innovate and scale, with a particular emphasis on digital financial inclusion; 01F GPS (Global Partner Solutions) scales proven technologies into global market leaders through execution-focused partnerships and joint ventures; and the 01F Intelligence Fund, an investment platform focused on trusted AI systems for the global economy.

Together, 01Fintech, 01F GPS and the 01F Intelligence Fund reflect the Group’s long-term approach to technology value creation: backing category‑defining companies, commercialising proven technologies globally and participating in the next wave of growth across fintech, AI and the wider digital economy.

For more information, please visit www.01fgroup.com.

About DANA

DANA (PT DANA Digital Group) is Indonesia’s leading digital financial platform, playing a pivotal role in advancing financial inclusion and accelerating the country’s digital economy through secure, trusted, and innovative financial services. Since 2018, DANA’s integrated ecosystem, including digital payments, QRIS, money transfers, and AI-powered financial solutions, empowers millions of users, businesses, and financial institutions. DANA continues to advance AI innovation, cybersecurity, and fraud prevention, delivering secure financial experiences while helping improve the financial wellbeing of Indonesians.

SOURCE 01F Group

During this past week, South Korea and Kazakhstan signed commercial agreements worth US$18.95 billion. Kazakhstan is a country of 20 million people with its core industries being oil and gas, and among the highest producers of iron and silver in the world. Uzbekistan is a country of 39 million people, and they are the largest electricity producer in Central Asia.

Qazaqstan Investment Corporation (QIC) is Kazakhstan’s national fund of funds and are anchor investors along with IT Park Ventures, the venture capital arm of the country’s state technology park. The new venture capital fund will back Central Asian startups at the Series A and later, which are businesses with a proven model that are ready to scale beyond the region. The fund is sector-agnostic but focuses on AI-native companies, where artificial intelligence is core to the product and business model.

“Higgsfield becoming Kazakhstan’s first unicorn was a turning point. It showed that a world-class AI company can be built in Central Asia. And it won’t be the last with more than half of the region’s population is under 30, growing up digital and our governments actively investing in AI. Yet the region is still largely overlooked by international investors, and that’s the opportunity this fund is built for,” explained Aslan Sultanov, Co-founder and General Partner at SparkLabs Mirae Silk Road.

Former Coinbase CTO and Partner at Andreessen Horowitz, Balaji Srinivasan, reopened his Network School in Kazakhstan last month. Telegram launched an AI lab and opened their first regional office in Kazakhstan this past year.

Beyond capital, portfolio companies will gain access to the SparkLabs and Mirae Asset’s global networks, along with hands-on support in expanding into South Korea, the United States and the MENA region.

About the Partners

SparkLabs Group is a network of startup accelerators and venture capital funds that has invested in over 600 startups across 6 continents since December 2013. These companies include OpenAI, SpaceX, Vectara, Kneron, Anthropic, Nex Team, Kraken, GenG, Lyft, MetAI, and others.

Mirae Asset Venture Investment is the venture capital arm of Mirae Asset Financial Group, one of Asia’s largest independent financial groups with over US$845 billion in assets under management. The company operates worldwide across 18 markets, and manages a fully diversified global investment platform encompassing ETFs, alternative investments, and traditional strategies.

Qazaqstan Investment Corporation (QIC) is Kazakhstan’s national fund of funds and part of Baiterek National Managing Holding. QIC invests in private equity and venture capital funds alongside international and private partners, with the goal of attracting long-term capital into Kazakhstan and developing the country’s investment ecosystem. QIC participates in 19 funds with a combined capitalization of $2.8 billion.

IT Park Ventures is the venture capital arm of IT Park Uzbekistan, the country’s state technology park and the main platform supporting Uzbekistan’s IT industry and tech exports. IT Park Ventures invests in startups from Uzbekistan and Central Asia and co-invests with international funds, connecting regional founders with global capital and markets.

SOURCE SparkLabs Group

SHANGHAI, Sept. 20, 2026 — The inaugural S2S China Symposium has announced the finalists of its 2026 program. Co-hosted by RA Capital Management and Qiming Venture Partners, S2S China is the China chapter of Science2Startup, an invitation-only symposium connecting top academic researchers with leading biotech investors. Ten standout biotech startup teams were selected from a highly competitive pool of applicants. They will refine their projects through a dedicated mentorship program and pitch to top global venture investors at an on-site event held at Westlake University on October 15.

S2S was founded in 2018 by F-Prime, SV Health and Atlas Venture; RA Capital Management, Osage University Partners and 5AM Ventures have since joined the program. It connects therapeutics researchers at top academic and research institutions with leading biotech investors, pharma scouts, and industry executives. The program provides selected teams with mentorship and a platform to present novel, proprietary science with a path toward company formation and clinical development.

This year’s S2S China drew enthusiastic participation from researchers and early-stage founders across China’s therapeutics research ecosystem. Following multiple rounds of rigorous review by an advisory group of experienced biopharma investors, the competition narrowed a large field of submissions to roughly 20 semifinalist teams, and ultimately selected ten standout teams to advance to the finals and present at the October 15 on-site pitch event.

To help the participating teams connect effectively with the capital markets and strengthen their overall project framework, the finalists will take part in a dedicated mentorship program ahead of the event. Over the coming weeks, the teams will work alongside the S2S China Symposium advisory group, made up of experienced biotech investors and industry operators, to refine their scientific plans, sharpen their commercial narratives and polish their pitch content, raising the maturity of each project and laying a solid foundation for the on-site presentations and funding conversations that follow.

This year’s S2S China Symposium is supported by prominent figures from academia and the global life sciences investment community, including Shi Yigong, President of Westlake University; Kan Chen, Partner and Healthcare Co-Lead at Qiming Venture Partners; and Josh Resnick, Partner at RA Capital Management. Their deep involvement underscores the symposium’s value as a bridge between China’s academic research ecosystem and the global biotech venture community, while continuing the model established by the original Science2Startup symposium.

The event brings together a number of globally recognized institutions and biopharma leaders, forming a powerful supporting ecosystem. This year’s S2S China Symposium would not be possible without the strong support of leading companies across the industry, including our Platinum Sponsors Goodwin, Eli Lilly and Biocytogen, as well as Johnson & Johnson (Gold Sponsor) and Sanofi (Silver sponsor). The partnership of our sponsors reflects a shared commitment to advancing early-stage, academically-derived therapeutics innovation from China onto the global stage.

Platinum Sponsors

Goodwin is a global law firm at the intersection of capital and innovation, representing innovators and investors across healthcare, investment funds & capital, life sciences, private equity, real estate, and technology.  With more than 2,800 professionals worldwide, Goodwin combines industry knowledge, legal excellence, and business advisory expertise to help clients navigate complex challenges and seize opportunities in a rapidly changing, technology-driven economy.  We represent clients throughout the full corporate lifecycle, including company formation, financings, capital markets transactions, licensing and collaborations, M&A, regulatory matters, and exit strategies.  Learn more: https://www.goodwinlaw.com/en

Eli Lilly and Company is a global pharmaceutical leader headquartered in Indianapolis, Indiana, dedicated to discovering and delivering medicines that make life better for people around the world. With a deep commitment to scientific innovation, Lilly has been an active partner to the region’s biotech ecosystem, supporting early discovery through late-stage development across a range of therapeutic areas.

Biocytogen is a global biotechnology company discovering and developing next-generation antibody therapeutics across multiple modalities. The company has built a broad portfolio of novel drug candidates spanning monoclonal and bispecific antibodies, ADCs, VHH-based therapeutics, and other antibody-based modalities, with multiple programs advancing into clinical development both internally and through global licensing partnerships. Powered by its proprietary RenMice® platforms and large-scale antibody discovery engine, Biocytogen has generated more than one million fully human antibody sequences across over 1,000 therapeutic targets and established partnerships with more than 455 biopharmaceutical companies worldwide.

Gold Sponsor

Johnson & Johnson is a global healthcare leader, headquartered in New Brunswick, New Jersey, committed to solving the toughest health challenges and transforming lives through research, development, manufacture and distribution of medicines and medical technologies. The company’s Innovative Medicine business advances breakthrough science and develops transformational treatments in areas like oncology, immunology, neuroscience, and cardiopulmonary. In MedTech, the company is focused on developing and delivering cardiovascular, surgery, and vision solutions.

Silver Sponsor

Sanofi is a global biopharmaceutical company headquartered in Paris, France, dedicated to pursuing scientific breakthroughs that improve people’s lives. The company focuses on immunology, oncology, neurology, rare diseases, ophthalmology and vaccines, and maintains a significant R&D and commercial presence in China, where it has long invested in partnerships with local academic and biotech innovators to expand its global pipeline.

More information is available at s2schina.com/s2s/en.

About Qiming Venture Partners

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages.

Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status.

Many of our portfolio companies are today’s most influential firms in their respective sectors, including  Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Hesai Technology, UBTech, WeRide, HyperStrong, Insta360, Unisound, Biren Technology, Z.ai, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, Sanyou Medical, AmoyDx, SinocellTech, Insilico Medicine, AusperBio, Yuanxin Technology, Medilink Therapeutics, LaNova Medicines, StepFun, among many others.

LONDON, Sept. 18, 2026 — Nscale Limited (“Nscale”) today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Nscale has applied to list its ordinary shares on the New York Stock Exchange under the ticker symbol “NSCL.”

Goldman Sachs & Co. LLC, J.P. Morgan and Morgan Stanley will act as lead bookrunners for the proposed offering. RBC Capital Markets, BofA Securities, Deutsche Bank Securities, Credit Agricole CIB, TD Securities, Mizuho, KeyBanc Capital Markets, Cantor, SMBC Nikko and Wolfe | Nomura Alliance will act as bookrunners for the proposed offering.  Citizens Capital Markets, Loop Capital Markets, Roth Capital Partners, ABN AMRO, Compass Point, DNB Carnegie, Rosenblatt, SEB and Tigress Financial Partners will act as co-managers for the proposed offering.

The proposed offering will be made available only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282 or by email: [email protected]; J.P. Morgan Securities LLC, Attention: c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email: [email protected] and [email protected]; or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick St., 2^nd Floor, New York, New York 10014.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Nscale

Nscale Limited (Nscale) is a full-stack AI cloud platform. We bring together software, compute, and power in a vertically integrated offering – from a unified cloud platform for running AI training and inference, to the data centers and low-cost power that make it possible. Our mission is to build the engine of superintelligence and enhance access to the benefits of advanced AI for enterprises, governments, and the communities that depend on them.

SOURCE Nscale

DALLAS, Sept. 18, 2026 — Vestie is an investing platform designed for beginner investors, specifically women, who want to start investing but don’t know what to buy, when to start, or how to build a portfolio.

Vestie’s philosophy is simple: You don’t need to become a stock market expert to build wealth. Vestie is designed to help people start investing, automate the process, and stay invested for the long term. It’s your investing bestie — making investing feel more like getting help from a knowledgeable friend and less like walking into a Wall Street trading desk.

Founder and CEO Dana Bentz created Vestie after seeing how intimidating investing can feel to people who weren’t already immersed in finance. She built the product she wished existed when she first decided, “Okay, I know I should invest… Now what?” Most investment platforms were built around either active trading or traditional financial advisory experiences, and feature difficult-to-understand dashboards. Vestie is intentionally designed around simplicity, automation, and a beginner-friendly experience.

Users answer a short onboarding questionnaire regarding their investing goals, experience, and risk tolerance. They then receive a recommended diversified portfolio based on their unique answers, connect their bank account, fund their account, and can optionally set up recurring investments.

Vestie, Inc. is an investment adviser registered with the U.S. Securities and Exchange Commission*. Dana Bentz serves as the company’s CEO and as an investment adviser representative of Vestie, and says, “A lot of women know they should be investing. The problem isn’t convincing them that investing matters; it’s making that first step feel supported and simple enough to actually take.”

The company built a waitlist of roughly 500 people before public launch, demonstrating demand before the full product was available. Vestie is subscription-based rather than relying on users to constantly trade. Users can get started completely free, with access to advanced features for $14 per month or $139 per year. Vestie’s ambition is to become the financial platform women rely on when they decide they want to start investing and building wealth.

Vestie is available at https://vestie.com/, where users can create an account and begin investing.

*Registration with the SEC does not imply a certain level of skill or training.

Kelsey Bentz, [email protected]

SOURCE Vestie, Inc.

• ImpriMed combines ex vivo functional testing with multimodal AI to support personalized cancer treatment decisions and drug development
• The investment is part of ImpriMed’s $10 million Series A2 bridge round as the company advances U.S. commercialization and expands into Asia
• NAVER D2SF to strengthen its global healthcare founder community through its healthcare network and go-to-market expertise

SEOUL, South Korea, Sept. 18, 2026 — NAVER D2SF, NAVER’s inhouse corporate venture arm, has invested in ImpriMed, a Silicon Valley-based precision medicine company, joining ImpriMed’s $10 million Series A2 bridge round. ImpriMed develops AI-driven precision medicine solutions that combine ex vivo analysis of patient-derived live cancer cells with genomic, immunophenotypic, and clinical data to support personalized treatment decisions. NAVER D2SF’s investment reflects ImpriMed’s commercial and clinical experience in the U.S. healthcare market and its growing capabilities across precision medicine and drug development.

Precision oncology increasingly relies on integrating multiple types of patient data to account for differences in disease biology and treatment response. ImpriMed applies multimodal AI to patient-specific cancer cell characteristics, drug response profiles, and clinical information to enable more personalized treatment selection.

At the core of ImpriMed’s xCellSense^® platform is its ability to keep patient cancer cells viable ex vivo for extended periods, enabling evaluation of their biological characteristics and drug sensitivity. The platform combines these results with immunophenotypic, genomic, and clinical data to guide treatment decisions. ImpriMed is developing AI models trained on more than 3.5 million data points, combining real-world data with functional cell analysis to improve predictive accuracy.

ImpriMed is preparing to commercialize products for blood cancers and blood infection, targeting FDA clearance and CLIA certification by Q1 2027 for an initial U.S. launch. The company has also established business partnerships with major U.S. hospitals as it builds its human health presence in North America. In South Korea, ImpriMed has developed software for multiple myeloma prognosis and therapy-response predictions. The software has been designated an Innovative Medical Device by the Ministry of Food and Drug Safety (MFDS) and is progressing through the approval and commercialization process. ImpriMed also collaborates with leading tertiary hospitals, including Catholic University Seoul St. Mary’s Hospital, Seoul Asan Medical Center, and Gangneung Asan Hospital.

ImpriMed’s human healthcare expansion is supported by its commercial experience in veterinary precision oncology and its growing CRO business in drug development. In veterinary medicine, ImpriMed has performed more than 27,000 tests for canine and feline lymphoma to guide treatment decisions. A retrospective study showed a threefold increase in survival time and a fourfold improvement in treatment response, and the findings have been published in a peer-reviewed scientific journal. ImpriMed’s solutions are currently used by more than 600 veterinary hospitals across the United States, Canada, the United Kingdom, France, and South Korea.

ImpriMed was co-founded in Silicon Valley by CEO Sungwon Lim and CTO Jamin Koo, who studied together at KAIST and Stanford University. The company brings together expertise in biomedical research, AI modeling, clinical collaboration, and commercialization. Beyond North America, ImpriMed plans to expand into the European and Asian markets.

The $10 million bridge round follows ImpriMed’s $23 million Series A in 2023. The round was led by LB Investment, with participation from new investors NAVER D2SF, Samsung Securities, and Alois Ventures, as well as follow-on investments from existing investors BonAngels and Han River Partners.

NAVER D2SF continues to invest in healthcare startups targeting the North American market. Through NAVER D2SF’s founder network, portfolio companies such as Soundable Health, PranaQ, and NubiLab share local market knowledge and operating experience, fostering collaboration across R&D and go-to-market strategy.

About NAVER D2SF

NAVER D2SF is NAVER’s in-house corporate venture arm, supporting startups through investment and collaboration. Founded in 1999, NAVER has been Korea’s leading search engine for more than 20 years and operates across commerce, content, fintech, and cloud services. Guided by its technology vision of D2 (For Developers, By Developers), NAVER continues to develop new technologies and build global partnerships.

To learn more, visit https://d2sf.naver.com.

SOURCE NAVER D2SF